Compounds > ci 988
Page last updated: 2024-09-02

ci 988 and Colorectal Neoplasms

ci 988 has been researched along with Colorectal Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Howes, LG; Morris, DL; Romani, R2

Other Studies

2 other study(ies) available for ci 988 and Colorectal Neoplasms

ArticleYear
Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo and in vitro.
    The Australian and New Zealand journal of surgery, 1996, Volume: 66, Issue:4

    Topics: Administration, Oral; Analysis of Variance; Animals; Cell Division; Colorectal Neoplasms; Drug Evaluation, Preclinical; Hormone Antagonists; Humans; Indoles; Male; Meglumine; Mice; Mice, Nude; Neoplasms, Experimental; Receptors, Cholecystokinin; Tumor Cells, Cultured

1996
Dose dependent in vivo inhibition of human colorectal cancer (LoVo) by the gastrin receptor antagonist, CI-988.
    Clinical and experimental pharmacology & physiology, 1996, Volume: 23, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Division; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Indoles; Male; Meglumine; Mice; Mice, Nude; Neoplasm Transplantation; Receptors, Cholecystokinin; Tumor Cells, Cultured

1996